MaaT Pharma Receives FDA Feedback

Following Pre-IND Meeting Supporting Continued Development of MaaT034 in Solid Tumors.

Positive pre-Investigational New Drug (pre-IND) interaction with the Food Drug Administration (FDA) on Chemistry, Manufacturing and Controls (CMC) and nonclinical topics supports MaaT034’s continued advancement
FDA alignment on the IND-enabling strategy indicates that no additional non-clinical studies are anticipated to be required to support the safety of MaaT034 administration